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Abstract 
Age-related macular degeneration (AMD) is the leading cause of severe vision 
loss in the developed world.  The lack of effective treatment modalities, coupled 
with evidence supporting an oxidative pathogenesis, has increased interest in 
the potential preventative role of nutritional supplementation.  
 
This article reviews seven randomised controlled trials (RCTs) that have 
investigated the role of nutritional supplementation in AMD.  Three of these 
trials reported a positive effect of nutritional supplementation on AMD; the Age-
Related Eye Study (AREDS), the Lutein Antioxidant Supplementation Trial 
(LAST), and the oral zinc trial by Newsome et al. (1988).  However, the oral zinc 
trial by Newsome et al. (1988) was unlikely to detect any difference between 
treatments smaller than 72%, and the AREDS results were based on a 
subgroup of their study population.  Lutein was considered for the AREDS 
formulation, but was not commercially available at that time. The findings of the 
LAST support a possible therapeutic role of lutein in AMD.  
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Introduction 
Randomised controlled trials (RCTs) are considered to be the gold standard in 
clinical research (Gray, 1997; Huwiler-Muntener, 2002).  The aim of this review 
is to evaluate RCTs that relate to the effect of nutritional supplements on age-
related macular degeneration (AMD).  RCTs involve random assignment of 
participants into treatment and placebo groups.  The advantage of trials of this 
type is the ability to reduce, by masking, the influence of confounding variables 
by random assignment of the treatment (intervention), and the ability to reduce 
bias or the possibility that any observed effect is due to other factors.  The term 
‘double-masked’ or ‘double-blinded’ refers to the fact that neither investigator 
nor participants know who is in the treatment or placebo group.  In RCTs 
designed to investigate the effect of nutritional supplements, this is usually 
achieved by coding of the tablet containers.  At the end of the trial period the 
code is broken and the gathered data analysed. 
In summary, any RCT will involve the following steps (Hulley et al., 2001): 
1. Sample selection from the population 
2. Baseline variables measured 
3. Participants randomised 
4. Interventions applied (one will be a placebo) 
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5. Follow up of the cohort 
6. Outcome variables measured 
7. Results analysed 
 
The role of nutritional supplementation in ocular health is of interest to eye care 
practitioners.  Many have expressed a need for clearer guidance regarding the 
recommendation of supplements to their patients (Evans, 2002; Stainer, 2002).  
The increase in advertising and marketing of nutritional formulations has, in 
turn, increased awareness of the potential benefits of these supplements within 
the general population. 
 
Terminology of age-related macular degeneration 
The International Classification and Grading System for Age-Related 
Maculopathy (ARM) and Age-Related Macular Degeneration (AMD) has been 
developed in an attempt to standardise terminology (Bird et al., 1995):   
 
ARM is characterised by soft, confluent drusen, areas of hyperpigmentation 
associated with drusen, areas of hypopigmentation of the RPE without any 
visibility of choroidal vessels associated with drusen (also known as ‘early 
AMD’). 
AMD is a late stage of ARM and includes both non-exudative and exudative 
macular degeneration. 
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In this article the terms ARM and AMD will be used according to this 
classification. 
 
Aetiogenesis of AMD 
AMD is the leading cause of blindness in the developed world (Klein et al., 
1992; Klein et al., 1995; Evans and Wormald, 1996).  Diet has been related to 
AMD as well as other chronic conditions such as hypertension and 
cardiovascular disease (Williams et al., 1971; Manson et al., 1991; Osilesi et al., 
1991; Jacques, 1992a; Jacques, 1992b; Gey et al., 1993; Vitale et al., 1993; 
West et al., 1994). 
 
Oxidation hypothesis 
One hypothesis for the aetiology of AMD involves the breakdown of antioxidant 
systems within the retina.  An antioxidant can be defined as ‘any substance that 
when present at low concentrations compared to those of an oxidisable 
substrate, significantly delays or prevents oxidation’ (Halliwell, 1999). In the 
retina, normal metabolic processes, as well as exposure to high-energy visible 
light generate potentially damaging, activated forms of oxygen (Eye Disease 
Case Control Study (EDCCS) Group, 1993) called free radicals.  Free radicals 
are molecules that have one or more unpaired electrons and are produced via 
the process of oxidation.    Normal aerobic metabolism produces free radicals 
such as superoxide, hydroxyl radicals, singlet oxygen radicals and hydrogen 
peroxide. Free radicals can initiate lipid peroxidation, which is thought to lead to 
oxidative damage to DNA, protein and carbohydrate within cells (Curcio and 
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Millican, 1999).  The retina is particularly susceptible to damage via this process 
for several reasons:     
 
1. Polyunsaturated fatty acids are abundant in the retina, particularly the 
macular region.  They are found in photoreceptor outer membranes and are 
readily oxidised (Machlin and Bendich, 1987; Beardsley, 1991; Van der Hagen 
et al., 1993). 
 
2. The retina is subjected to high levels of light exposure.  Light (particularly 
blue light) is a strong oxidising agent.  The simultaneous presence of light and 
oxygen promotes production of free radicals (Schalch, 1992). 
 
3. Phagocytosis, which itself produces free radicals, occurs within the retinal 
pigment epithelium (RPE). 
 
4. The retina is highly active metabolically and has a much higher blood flow 
than other tissues (Schalch, 1992). 
 
The body has several defence mechanisms against the production of free 
radicals. The first involves antioxidant enzymes such as catalase and 
peroxidase (Sies, 1991). Other micronutrients such as selenium, zinc, 
manganese, and copper facilitate these antioxidant enzymes (Sies, 1991; 
Bressler and Bressler, 1995). The second involves antioxidant nutrients such as 
vitamin E (alpha-tocopherol) (Machlin, 1980; Fukuzawa and Gebicki, 1983; 
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Ozawa et al., 1983; Burton et al., 1985; McCay, 1985), beta-carotene (Burton 
and Ingold, 1984a) and vitamin C (ascorbate) (Nishikimi, 1975; Bodannes and 
Chan, 1979; Bielski, 1982; Hemila et al., 1985; Sies, 1991). Other antioxidants 
believed to play a part in maintenance of ocular health include the carotenoids 
lutein and zeaxanthin (Snodderly et al., 1984). Further defence mechanisms 
include antioxidant compounds such as metallathionein, melanin, and 
glutathione, and DNA repair.  Compartmentalisation is another defence 
mechanism and this involves the separation of reactive oxygen species (ROS) 
from cellular components that are susceptible to oxidative damage (Sies, 1991).  
Insufficient intake of dietary antioxidant vitamins and minerals can decrease the 
efficiency of the body’s natural antioxidant systems and may allow cellular 
damage by free radicals (Machlin and Bendich, 1987; Pippenger et al., 1991). 
 
Other factors in AMD pathogenesis have been proposed, such as the declining 
function of Bruch’s membrane with age (Feeney-Burns and Ellersieck, 1985; 
Bird and Marshall, 1986; Chuang and Bird, 1988), vascular insufficiency  (Klein 
1999), and genetic predisposition (Hyman et al., 1983; Smith and Mitchell, 
1998). 
  
Bruch’s membrane deterioration  
As the conductivity of Bruch’s membrane declines with age (Feeney-Burns and 
Ellersieck, 1985; Bird and Marshall, 1986; Chuang and Bird, 1988); the 
consequential impedance of fluid flow from the RPE towards the choroid results 
in RPE detachment. Geographic atrophy may result if there is a reduction in 
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metabolic exchange between the choroid and the RPE.  The material in Bruch’s 
membrane may be derived from the RPE (Ishibashi et al., 1986; Sheraidah et 
al., 1993; Moore et al., 1995).  Blockage of nutrition or proliferation of choroidal 
blood vessels under the retina caused by this thickening of Bruch’s membrane, 
may initiate choroidal neovascularisation. These new blood vessels destroy 
structures around them as they grow (Silvestri, 1997). 
 
Vascular insufficiency 
Changes in choroidal circulation may effect the normal diffusion of substances 
and gasses across the RPE-Bruch’s membrane complex and have been linked 
with development of AMD (Verhoeff and Grossman, 1937; Potts, 1966; 
Kornzweig, 1977; Bischoff and Flower, 1983; Pauleikhoff et al., 1990). Removal 
of waste materials and disruption the supply of metabolites and gasses to the 
neural retina is disturbed.  Deterioration of the RPE may result from this build up 
of waste products. (Friedman et al., 1995).  
 
Genetics 
Several studies have shown that there is an increased risk of AMD with a 
positive family history (Hyman et al., 1983; Smith and Mitchell, 1998).   A 
genetic basis for AMD is supported by the occurrence of the condition in 
families. Genes for other macular dystrophies such as Stargardt’s macular 
dystrophy and Best’s vitelliform macular dystrophy have been mapped to 
specific chromosomes (Stone et al., 1992; Kaplan et al., 1993; Stone et al., 
1994; Zhang et al., 1994). AMD is a multifactorial condition and it is likely that 
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those with an inherited predisposition for the condition will develop it only with 
exposure to appropriate environmental factors (Bird, 1996; Silvestri, 1997). 
 
Clinicopathogenesis of AMD 
The first indication that the metabolic state of the normal, healthy retina has 
been altered can be seen as deposition of metabolic debris between the 
basement membrane of the RPE and Bruch’s membrane.  This accumulation of 
metabolic debris occurs in the senescent RPE and involves remnants of 
incomplete degradation from the phagocytosis of rod and cone cell membranes. 
Photoreceptor outer segments that are not digested in the lysosomes of RPE 
remain in the RPE cells as highly oxidised lipid material (lipofuscin) (Curcio and 
Millican, 1999).  Part of the accumulation of lipid material on the inner 
collagenous layer of Bruch’s membrane (Pauleikhoff et al., 1990) is clinically 
visualised as large drusen (Curcio and Millican, 1999), eventually leading to a 
drusenoid pigment epithelial detachment (PED).   Inflammatory cells are 
thought to invade the drusenoid PED, leading the way to choroidal 
neovascularisation (Algvere and Seregard, 2002).   
 
Inclusion criteria for review studies 
Type of study Randomised controlled trial comparing nutritional 
supplementation with a control. 
Type of intervention Any antioxidant vitamin or mineral, alone or in 
combination.  The vitamins or minerals have 
antioxidant properties themselves, or are a 
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component of an antioxidant enzyme within the 
retina. 
 
A literature search was carried out on Web of Science and PubMed using the 
terms, ‘age-related macular degeneration’, ‘macular degeneration’, ‘randomised 
controlled trial’,  ‘controlled trial’, ‘supplementation’, ‘antioxidant’, ‘carotenoids’, 
‘lutein’.  The reference sections of those papers located in this way were then 
searched for other relevant studies. 
 
RCTs included in this review are shown in table 1, and the nutrient amounts 
included in each study formulation are shown in table 2.  Recommended daily 
allowance (RDA) values for nutrients included in the review are shown in table 3 
(where RDA values have been determined). 
 
Insert table 1.  
Insert table 2. 
Insert table 3. 
 
Statistical analysis 
One way of comparing the reliability of RCTs is to calculate the ability of the trial 
to detect a difference between treatment means.  An approximate formula for 
this calculation is, 
 
R = 2C√2/√r   (Ridgman, 1975) 
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where ‘R’ is the percentage difference detectable in an experiment, ‘C’ is the 
coefficient of variation (the standard deviation as a percentage of the mean), 
and ‘r’ is the number of participants in each group.  For example, if R = 10% 
then a true difference between the treatments of less than 10% is unlikely to be 
detected by the trial (Armstrong et al., 2000).   
 
R values have been calculated for the trials shown in table 4 because C and r 
could be determined.  R values could not be calculated for the other trials 
reviewed because the required data was not available in the publications. 
 
Insert table 4 
 
Review of trials 
Zinc in AMD  
Subjects 
A computer-generated table of random numbers was used to randomise 151 
participants.  For inclusion visual acuity in one eye had to be 20/80 or better and 
ARM or AMD had to be evident by varying degrees of pigmentary change and 
drusen visualised with fundoscopy.   
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Experimental design 
The treatment group took one tablet containing 100mg of zinc sulphate twice 
daily and the placebo group took identical tablets containing lactose and 
fructose.  All tablets were provided in identical containers. 
 
Outcomes 
Visual acuity with current glasses, pinhole visual acuity, colour vision, glare 
recovery time and serum zinc levels were all recorded, as well as fundus 
photographs.  Masked independent observers graded baseline and final fundus 
photographs.   
 
It has been found that zinc interacts with copper by stimulating metallothionein 
levels of the intestinal wall.  Metallothionein binds to dietary copper preventing 
absorption, which leads to copper defiency.  This can result in copper deficiency 
anaemia, since copper is required for production of erythrocytes (Dunlap et al., 
1974; Fischer et al., 1983; Flanagan et al., 1983).  Although copper was not 
included in the intervention formulation, the hematocrit (percentage of the whole 
blood that is comprised of red blood cells) was determined serially throughout 
the study period for each subject.  No evidence of copper-deficiency anaemia 
was found.  
 
Results 
The investigators determined that the decrease in mean visual acuity in the zinc 
treated group was less than that of the placebo group (Newsome et al., 1988), 
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in other words, zinc reduced progression of AMD (see figure 1).  Figure 2 shows 
the change in the number of drusen assessed by each observer, for example, 
observer 1 found that 12 participants in the zinc group and 1 participant in the 
placebo group had fewer drusen at the end of the trial period than at baseline. 
 
 
Figure 1 (Newsome et al., 1988). 
 
Figure 2 (Newsome et al., 1988) 
 
Limitations 
Calculation of the R value for this trial shows that it was unlikely to detect any 
difference between treatments smaller than 72% and that the results should be 
treated with caution.  The authors suggest potential sources of bias including 
the use of subjects from a relatively small geographical area, and high soil and 
water mineral contents in this area. 
 
Although five different parameters were measured, it would have been 
beneficial to measure the refractive error of subjects at each visit rather than 
relying upon pinhole visual acuities.  The number of participants was small 
compared with the AREDS, ATBC and VECAT trials, but larger than the 
Visaline® trial.   The use of a single nutrient provides more specific information 
about the role of zinc in AMD. 
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Visaline® in the treatment of AMD 
Subjects 
This trial investigated the effect of Visaline® on the progression on AMD in 20 
subjects with early stages of the condition.   The subjects were over 50 years of 
age and had consulted an ophthalmologist due to non-exudative AMD.  Follow 
up occurred at 3 and 6 months. 
 
Experimental design 
Visaline® is registered in Switzerland for the treatment of AMD. Eleven patients 
were allocated to Visaline® and nine to the placebo.  Participants and 
investigators were masked as to intervention and placebo allocation. Two 
tablets were taken twice daily except for weekends, according to clinical 
recommendations. 
 
Outcomes 
Lens opacity was quantified with the Opacity Lens Meter (LOM) 701 (Interzeag, 
Switzerland), to assess the effect of cataract on results.  This instrument 
assesses cataract by measuring the degree of scatter of a red light beam 
(700nm) by the lens (Clarke et al., 1990; Costagliola et al., 1990).  Retinal visual 
acuity was measured using the Moire Interferometer (Haag-Streit, Berne, 
Switzerland).  Macular function was evaluated using the Octopus field tester, 
and distance and near visual acuity, intra-ocular pressure, fundus inspection, 
contrast sensitivity and the Pandel-15 colour vision test were also measured. 
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Results 
Results showed no significant difference in measured parameters between the 
intervention and placebo groups.   
 
Limitations 
The fact that no treatment effect was determined is unsurprising considering the 
small sample size and the calculated R value for the study of 89%. This means 
that the study was only likely to be capable of detecting a difference between 
treatments that was greater than 89%. Interestingly, the effect of the Visaline® 
was subjectively considered to be more effective than placebo, despite the fact 
that the trial was designed to be double-masked. Investigators hypothesise that 
this could be a result of increased cerebral perfusion of buphenine (Kaiser et al., 
1995), although no mechanism for this effect has been suggested.   No 
information is given about the appearance, taste or smell of the placebo and 
intervention tablets, or about their packaging.  It is possible that masking was 
not complete. As with AREDS and the ATBC study, the intervention formulation 
contained more than one substance, limiting the conclusions that may be drawn 
regarding specific nutrients.   
 
Insert figure 3 
 
An advantage of this trial is the fact that several visual parameters were 
measured.    
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Zinc and the second eye in AMD  
This study investigated the effect of zinc supplementation on progression to 
exudative AMD in the second eye of patients with an exudative form of the 
disease in the first eye (Stur et al., 1996).   
 
Subjects 
One hundred and twelve subjects were enrolled, presenting with AMD and 
exudative lesions in one eye with a visual acuity better than 20/40, and AMD 
without any exudative lesion in the second eye.   
 
Experimental design 
Subjects were randomised into two groups, one receiving 200mg of zinc 
sulphate and the other receiving placebo, once daily.  Tablets were coded and 
provided in identical containers, so that participants and investigators were 
masked.  Intervention and placebo tablets were lemon flavoured and 
effervescent to improve gastrointestinal absorption. 
 
Outcomes 
Outcome measures were visual acuity, contrast sensitivity, colour discrimination 
and retinal grating acuity, as well as serum levels of zinc and copper, red blood 
cell count, and grading of fundus photography.  This trial was the only one to 
include and grade fluoroscein angiography.  Again, copper was not included in 
the intervention formulation but no significant change in red blood cell count 
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was found during the treatment period, providing no evidence for onset of 
copper-deficiency anaemia. 
 
Results 
Investigators concluded that oral zinc substitution had no short-term effect on 
the course of AMD in patients with an exudative form of the disease in one eye. 
 
Limitations   
The investigators planned to recruit 500 participants, and had calculated the 
power of the trial to be >80% based on this sample size.  Recruitment was 
stopped in June 1993 after statistical evaluation by their sponsors failed to show 
any treatment benefit.  The calculated R value suggests that the trial was likely 
to be able to detect a treatment effect greater than 16%, which is a much 
greater degree of precision than the Newsome et al. (1988) study.   
 
Alpha-tocopherol Beta-carotene Study (ATBC) 
Subjects 
This trial was originally designed to investigate the role of BC and vitamin E 
(AT) in the prevention of lung cancer in over 29,000 smoking males.  At the end 
of the trial an ophthalmological examination was carried out on a random 
sample of 941 male participants aged 65 years or over, to determine whether 
intervention with AT and/or BC had been associated with a difference in AMD 
prevalence (Teikari et al., 1998). The size of the main cancer trial provided a 
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large base from which to select participants for the AMD branch, and the 
timescale increased the likelihood of determining change.  
 
Experimental design 
Participants were randomised into four groups, 1) AT only, 2) BC only, 3) AT 
and BC, 4) placebo.  No information is provided about the appearance or 
packaging of the placebo and intervention tablets, but they are assumed to be 
identical as the original trial was designed to be double-masked and placebo-
controlled.  
 
Outcomes  
This trial examined the inter-group differences in AMD prevalence.  The level of 
AMD was assessed from fundus photography 
 
Results 
Investigators concluded that long-term supplementation of AT or BC does not 
affect the prevalence of ARM in smoking males (Teikari et al., 1998).  Figure 4 
shows the distribution of ARM and AMD by treatment group. 
 
Insert figure 4 
 
Limitations 
A disadvantage of the study is that fundus photographs were not taken at 
baseline, which means that intra-group variation could not be assessed.   The 
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study was not likely to be powered to assess treatment effects for AMD as the 
number of participants graded with disciform degeneration or geographical 
atrophy was just 8/237 for AT, 3/257 for ATBC, 0/234 for BC, and 1/213 for 
placebo. 
 
The study could have been improved by including measurement of clinical 
visual parameters such as central visual field analysis, colour vision, contrast 
sensitivity, and glare recovery.  An equal spread of AMD at baseline is assumed 
due to randomisation, as well as the fact that mean visual acuity was similar in 
all four groups.  Baseline visual acuity was also similar between those who 
chose to take part in the AMD section of the trial and those who did not, 
suggesting that selection bias is unlikely.  
 
Age-Related Eye Disease Study (AREDS) 
The AREDS trial had two main branches investigating the role of high dose 
nutrient supplementation on both AMD and cataract.  This review will mainly 
discuss the results of the AMD branch.   
 
Subjects 
Eleven retinal speciality clinics enrolled 3640 subjects from 1992 to 1998.  
Potential participants were identified from medical records of patients seen at 
AREDS clinics, referring physicians, patient lists from hospitals and health 
maintenance organisations, public advertisements, friends and family of study 
participants, screenings at shopping centres, health fairs, senior citizen centres 
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and other gathering places.   The range of ages was 55-80 years with an 
average of 69 years.  The following inclusion criteria were used; 20/32 in one 
eye, clear ocular media for fundus photography and one eye free from any 
disease that could complicate assessment of AMD.  Participants were grouped 
into four main categories according to ARM or AMD stage, as shown in table 5. 
 
Insert table 5. 
 
Participants in categories 2, 3 and 4 took part in both AMD and cataract 
branches and were randomised into four arms; 1) antioxidants, 2) zinc, 3) 
antioxidants plus zinc, 4) placebo.  Category 1 patients (those showing no signs 
of ARM or AMD) were only included in the cataract branch and so were 
randomised into antioxidant and placebo arms only.  Zinc supplementation was 
not investigated in the cataract branch due to the lack of evidence for any 
beneficial effect of zinc supplementation on the progression of lens opacities, 
combined with the possible toxic effects of zinc. 
 
Experimental design 
The treatment and placebo tablets were allocated in coded bottles and 
participants and providers were masked. The placebo used in AREDS was 
identical in external appearance and similar in taste and internal appearance, to 
the active tablet.   See table 2 for the formulation of the active tablets. 
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Some nutritional supplement ingredients degrade throughout the life of the 
product and before the expiry date.  Nutritional products are formulated with 
slightly different amounts of ingredients than listed in order to achieve 
appropriate potency at the expiry date.  The AREDS tablets were formulated 
to give the following minimum amounts of each ingredient throughout the shelf 
life of the product:   
Vitamin C (ascorbic acid)    113mg 
Vitamin E (dl-alpha tocopheryl acetate)  68mg  (100IU) 
Vitamin A (beta-carotene)    4871mg (7160IU) 
Zinc (zinc oxide)     17.4mg 
Copper (cupric oxide)    0.4mg 
    
Cupric oxide was added to the tablet formulation to offset the risk of copper 
deficiency anaemia.  Vitamin C, vitamin E and zinc were included at much 
higher levels than RDA (see table 3).  There is no RDA for beta-carotene.  Two 
years into the AREDS the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer 
prevention Study group proved a relationship between beta-carotene and 
increased incidence of lung cancer in smoking males (The ATBC Cancer 
Prevention Study Group, 1994) .   This was followed in 1996 by a report from 
the Beta-Carotene and Retinol Efficacy Trial  (CARET) who noted that 28% 
more of the subjects taking beta-carotene developed lung cancer (Leo and 
Lieber, 1997).  In 1996, smokers taking part in AREDS were given the option of 
discontinuing supplementation.    Two percent (18% of smokers in AREDS) 
discontinued supplementation in 1996. 
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Outcomes 
AMD was assessed using fundus photography and visual acuity was measured 
using logMAR EDTRS charts.  Primary outcomes were progression to 
advanced AMD (AMD event) and a 15 letter or more decrease in visual acuity 
score (VA event). An AMD event was considered to be the development of 
neovascular AMD or development of geographical atrophy that involved the 
central macula.   
 
Results  
Table 6 shows the probability estimates of AMD events for each AMD category 
after five years. 
 
Insert table 6. 
 
In category 2, only 15 AMD events occurred after five years and these were 
evenly distributed across treatment arms.  The investigators considered it 
impossible to assess treatment effects in this category with such a low event 
rate.  Table 7 shows the probability of progression to advanced AMD by 
treatment arm for categories 3 and 4. 
 
Insert table 7. 
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There was a 25% reduced risk of disease progression in those participants 
taking zinc plus antioxidants with intermediate or large drusen, non-central 
geographic atrophy, or advanced AMD in the second eye, as well as a 
‘suggestive’ reduction in risk for the zinc arm (see figure 5).   
 
Insert figure 5  
 
Table 8 shows the probabilities of a visual acuity event (at least a 15 letter 
decrease in visual acuity score) between baseline and five years for categories 
3 and 4.   
 
Insert table 8. 
 
Analysis of the results from categories 3 and 4 show a statistically significant 
reduced risk of a visual acuity event occurring in the antioxidant plus zinc arm 
compared to the placebo arm. 
 
Definite serum responses to the study antioxidants were observed and are 
shown in tables 9 and 10. 
 
Insert table 9. 
Insert table 10. 
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Participants taking zinc had an 18% increase in median serum level of zinc from 
baseline to year 1.  This was maintained throughout the 5-year period.  
Participants not assigned to a zinc group had smaller increases of 3% and 1%.  
The median percent changes in serum levels of copper ranged from a 3% 
decrease to a 2% decrease across all treatment arms, indicating that copper 
levels were not affected by intervention of zinc oxide with cupric oxide.   
 
These results suggest that the combination of zinc and antioxidants was 
‘modestly’ effective in preventing progression to advanced AMD (The AREDS 
Research Group, 2001).  This effect was seen only in those subjects with 
extensive intermediate drusen, large drusen or non-central geographic atrophy 
without advanced AMD.  The effect was not seen with antioxidants alone, or in 
subjects with earlier or later stages of the condition.  There was no statistically 
significant effect of delaying the progression of baseline category 2 eyes to 
categories 3 or 4. The trial was likely to be adequately powered to assess this. 
 
Limitations 
In an attempt to standardise extra supplementation, the investigators asked 
participants who were already supplementing with zinc or antioxidants (57%) to 
agree to take Centrum (Whitehall-Robins Healthcare, Madison, NJ) rather than 
any other nutritional supplements.   Centrum was supplied to 95% of these 
participants, as well as an additional 13% who were not taking supplements 
when recruited.  It would have been inappropriate to ask participants to stop 
taking other supplements as a pre-requisite to recruitment into the study. 
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It has been argued that the reason an effect was found was because 
participants were also taking Centrum (Abramson and Abramson, 2002).  
Centrum, however, provides nutrients in concentrations of no more than 100% 
RDA (for nutrients where RDA values have been determined), and these levels 
could be obtained from the diet.  As the intervention formulation introduced the 
study nutrients in much higher concentrations than RDA, the effect shown is 
more likely to be attributable to this and not variations in diet or extra 
supplementation.   
 
Statistical analysis was restricted to a subgroup of categories 3 and 4, which 
goes against standard clinical trial practice.  AREDS investigators state that 
subgroup analysis was appropriate in this case as only 15 out of the expected 
50 category 2 participants developed AMD (The AREDS Research Group, 
2001).  The statistical analysis method used by the AREDS Group does not 
allow the calculation of R, so that a measure of the degree of precision of this 
experiment cannot be determined.  The AREDS investigators calculated that a 
sample size of 3600 would provide at least 80% power to detect a treatment 
effect of 25% to 50% on progression to advanced AMD.  This sample size, 
however, included the category 2 participants. 
 
The results of this trial may support the oxidative stress hypothesis for 
development of AMD.  Unfortunately, it is not known whether this effect was 
initiated by one, or all of the nutrients, and to what degree.  There was no 
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statistically significant evidence to show that the intervention slowed the 
progression of ARM.   
 
Summary 
This trial forms an excellent platform for further research into the effect of 
nutritional supplementation on AMD.  The outcome of this study highlights a 
need for the investigation of, short-term supplementation, individual nutrient 
supplementation, and the role of nutritional supplementation in preventing the 
onset of AMD.  The AREDS investigators state that lutein and zeaxanthin were 
considered for inclusion in the formulation but that neither was readily available 
for manufacturing to a research formulation at AREDS initiation (The AREDS 
Research Group, 2001).  The role of lutein and zeaxanthin in prevention of 
development and progression of AMD was highlighted for further research.   
 
Vitamin E, cataract, and age-related maculopathy trial (VECAT) 
The purpose of the AMD branch of this trial was to determine whether vitamin E 
supplementation influences the incidence or rate of progression of AMD (Taylor 
et al., 2002).  
 
 
Subjects 
In total 1193 participants were randomised into two groups and followed up for 
four years.  The investigators use the term ‘early AMD’ as opposed to ARM and 
the grading system used is shown in table 11. 
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Insert table 11. 
 
Experimental design 
The intervention group took 500IU (approximately 335mg) of d-α tocopherol 
daily for four years.  The placebo was identical in sight, taste and smell. 
 
Outcomes 
The primary outcome was development of ‘early AMD 3’ and secondary 
outcomes were the progression of AMD and development of late AMD, changes 
in visual acuity and changes in visual function.  Visual function was measured 
using the Visual Function Index (VF-14) (Linder et al., 1999).  The incidence of 
early AMD was defined as the appearance of early AMD in at least one eye of 
participants who did not have early AMD in either eye at baseline. 
Stereophotographs of the macula were graded independently.   
 
Results 
No significant difference was found in incidence or progression of early AMD 
between intervention and placebo groups.  The trial concluded that daily 
supplementation with vitamin E does not prevent development or progression of 
early AMD (Taylor et al., 2002). 
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Limitations 
No measurement of the degree of precision of the trial is available as the data 
provided does not permit calculation of R.  The trial is unlikely to be adequately 
powered for assessment of treatment effect in the ‘early AMD 4’ and ‘late AMD’ 
categories as photographs graded for these groups constituted only 2% (vitamin 
E) and 3% (placebo) of the participants at 4 years.  Having said this, 
photographs appear to have been graded for a total of 56% of the vitamin E 
group and 61% of the placebo group at baseline, and 55% and 54% 
respectively at four years.  This could indicate that the remaining photographs 
were not of high enough quality for grading purposes, and the 7% reduction in 
the number of photographs graded between baseline and four weeks in the 
placebo group may suggest a high drop-out rate. 
 
The trial was designed with the measurement of various outcome parameters 
and the masking of treatment and placebo groups. Measurement of parameters 
such as glare recovery, contrast sensitivity and colour vision would have 
enhanced the trial. The intervention however, contained a single nutrient, which 
provides a more conclusive answer to the role of vitamin E in AMD. 
 
 
 
The Lutein Antioxidant Supplementation Trial (LAST) 
The results of this RCT investigating the role of lutein on progression of atrophic 
AMD have been published in abstract form.   
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Subjects 
Ninety, mostly male veterans (74.7 +/- 7.1 years) with atrophic AMD were 
recruited. 
 
Experimental design 
Participants were randomised into three treatment groups; 1) 10mg lutein, 2) 
10mg lutein/antioxidants, 3) placebo, and were matched for age, years 
diagnosed with AMD, smoking/cardiovascular history, iris colour, lens 
opacification and nutritional status/activity level.   
 
Outcomes 
Outcome measures were macular pigment optical density (MPOD) 
measurement, lens opacification rating, glare recovery, low-luminance low-
contrast visual acuity, contrast sensitivity, and activities of daily living associated 
with AMD (night driving/glare adaptation disturbance). 
 
Results 
Investigators have reported a statistically significant concurrent improvement in 
glare recovery, contrast sensitivity, and distance/near visual acuity in both 
treatment groups.  Combining lutein with other antioxidants appears to provide 
added improvement to contrast sensitivity (Richer et al., 2002). 
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See table 12 for a summary of the outcomes of the RCTs discussed in this 
review. 
 
Insert table 12. 
 
 
Discussion 
Vitamin C in AMD 
Vitamin C is a water-soluble antioxidant and acorbic acid has been shown to 
react directly with hydroxyl radicals (Bielski, 1982), superoxide (Nishikimi, 1975; 
Hemila et al., 1985), and singlet oxygen (Bodannes and Chan, 1979). The 
EDCCS reported that low plasma levels of vitamin C were associated with 
increased risk of AMD, but high levels were not found to be protective (EDCCS 
Group, 1993).  Its role in protecting against free radical-mediated oxidative 
tissue damage may have wide implications in retarding disease progression 
(Department of Health, 1992).    
 
 
Vitamin E in AMD 
Vitamin E exists in four common forms; α-tocopherol, β-tocopherol, γ-
tocopherol, and δ-tocopherol (Drevon, 1991).  The most predominant form in 
the human retina and plasma is α-tocopherol (Handelman et al., 1985; Alvarez 
et al., 1987), which is also the most effective scavenger of free radicals (Burton. 
and Ingold, 1984). Evidence that it may protect against AMD comes from 
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observational evidence of dietary and blood levels of vitamins and nutrients in 
AMD patients (Teikari et al., 1998). It is found in high concentrations within the 
retina (Dilley, 1970; Hunt, 1984), and as the major lipid-soluble antioxidant 
present in all cellular membranes, protects against lipid peroxidation (Machlin, 
1980).   Vitamin E may also have a role as a quencher of singlet oxygen and 
plasma concentration reduces with age.   Higher dietary intake of vitamin E can 
increase its concentration in the retina (Seddon, 1999), and a relationship has 
been found between greater plasma vitamin E levels and a reduced risk of AMD 
(Delcourt et al., 1999). 
 
Zinc in AMD 
Zinc is highly concentrated in ocular tissues, particularly the retina and pigment 
epithelium (Siegel et al., 1961; Galin et al., 1962; Swanson and Truesdale, 
1971; Eckhert, 1979; Ujiie, 1979).  It acts as a cofactor for the antioxidant 
enzymes retinal dehydrogenase and catalase (Sigel, 1983) and is also involved 
in retinal metabolism.  The elderly are at risk from zinc deficiency (Solomons, 
1979; Turnland et al., 1981; Wagner et al., 1983; Wagner, 1985), which can 
lead to a reduction in T lymphocytes and B lymphocytes through increased 
apoptosis. Zinc deficiency also compromises the function of another 
immunological cell, the macrophage (Berger, 2002). 
 
Zinc is the second most abundant trace mineral in the body (Karcioglu, 1982) 
and plays a part in numerous enzyme systems within the eye, including alkaline 
phosphatase, carbonic anhydrase (important in aqueous production) and 
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enzyme systems concerned with metabolism and nucleic acids (Karcioglu, 
1982).  Zinc is a cofactor for retinal dehydrogenase, which is involved in 
metabolism of a vitamin A transport protein, and also the interconversion of 
retinol to retinal, which is essential for rhodopsin synthesis (Solomons and 
Russell, 1980).  Zinc deficiency can alter the function of alcohol dehydrogenase 
in the retina (Huber and Gershoff, 1975), which can result in increased overall 
vitamin A uptake.  The possible accumulation of retinyl esters in the RPE may 
interfere with normal biosynthesis and could also produce a toxic effect.  In the 
same way, zinc deficiency promotes lipid peroxidation and damage to lipid 
membranes (McClain et al., 1985). 
 
Beta-carotene in AMD 
Carotenoids are regarded as effective antioxidants and beta-carotene has a 
well documented role as a quencher of singlet oxygen radicals (Burton and 
Ingold, 1984a).  They are pigments which exist in marigolds, coloured fruit and 
dark green, leafy vegetables (Khachik and Beecher, 1987; Khachik and 
Beecher, 1988; Khachik et al., 1989; Ong and Tee, 1992; Mangels et al., 1993; 
Sommerburg et al., 1998).  Beta-carotene is the major carotenoid precursor of 
vitamin A.  Vitamin A cannot quench singlet oxygen and has only a very small 
capacity to scavenge free radicals (Urbach et al., 1951; Mathews-Roth, 1986).  
 
Protective role of carotenoids in AMD 
Over recent years the amount of evidence supporting the protective role of 
carotenoids in the retina has increased.  Lutein, zeaxanthin, and meso-
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zeaxanthin, which are oxygenated carotenoids known as xanthophylls, form  the 
macular pigment (MP) (Bone et al., 1985; Khachik et al., 1997).  It has been 
shown that the xanthophylls have superior antioxidant properties to 
hydrocarbon carotenoids such as beta-carotene and exhibit a smaller tendency 
towards pro-oxidant behaviour (Martin et al., 1999).   These nutrients are 
obtained by the human body exclusively from dietary sources (Khachik et al., 
1991; Khachik et al., 1992)  and are, for example, found in marigold flowers, 
mango, papya, kiwi, peaches, spinach, squash, and honeydew melon.  The 
normal Western diet contains 1.3-3mg per day of lutein and zeaxanthin 
combined (Landrum and Bone, 2001); the recommended daily intake of lutein is 
6mg (Seddon, 1999).  This value was determined by the EDCCS group, where 
investigators found that participants with a daily lutein intake above the highest 
quintile (6mg) had a decreased risk of neovascular AMD (EDCCS Group, 
1992). 
 
Lutein and zeaxanthin reach their greatest concentrations at the centre of the 
fovea and diminish with eccentricity (Snodderly et al., 1991; Hammond et al., 
1997; Beatty et al., 1999; Landrum and Bone, 2001).  They are present in the 
axons of the photoreceptors and are responsible for the ‘yellow spot’ at the 
macula (Snodderly et al., 1984).  In vivo the ‘yellow spot’ appears dark when 
viewed under blue light due to the absorption of the blue wavelengths by the 
yellow pigment (Schalch, 2001).  Wald first demonstrated that this macular 
pigment exhibited a characteristic xanthophyll absorption spectrum (Wald, 
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1945), and later, the presence of lutein and zeaxanthin in the macula was 
established (Handelman et al., 1988).  
 
The MPOD can vary within an individual depending on diet and lifestyle (Beatty 
et al., 2000).  Psychophysical techniques used to measure the quantity of MP in 
the living eye include colour matching, motion anomaloscope, spectral 
sensitivity and heterochromic flicker photometry (HCFP) (Mellerio, 2001; 
Bernstein, 2002).  Until recently HCFP has been the most commonly used 
technique, the basic is theory based on the difference between foveal and 
parafoveal sensitivities to blue light being used as a measure of optical pigment 
density (Mellerio, 2001).   Most recently, a technique based on resonance 
Raman spectroscopy has been used.  Most compounds scatter monochromatic 
light at the same wavelength, a phenomenon called Rayleigh scattering.  A 
small proportion of the monochromatic light is scattered at different wavelengths 
that are determined by the molecular structure of the compound, a phenomenon 
known as Raman scattering.  All carotenoids measured in vivo or in vitro have 
very similar Raman spectra because they share a similar chemical structure.   
This technique is valuable as an objective measure of macular pigment levels, 
as opposed to the subjective flicker photometry.  Studies using this technique 
have determined that macular pigment levels decline with age and that levels 
are significantly lower in non-supplemented AMD eyes compared with age-
matched controls (Bernstein, 2002).   
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Low MPOD, measured using a flicker photometry-based technique, has been 
found in obese subjects compared with those of normal weight.  The MPOD of 
subjects with body mass index (BMI) greater than 29 was 21% less than 
subjects with a lower BMI (Hammond et al., 2002).  This could be explained by 
the fact that up to 80% of the total carotenoids in the body are found in adipose 
tissue (Olson, 1984).   Another study using scanning laser ophthalmoscopy and 
reflectometry techniques found that a daily dose of 6mg of lutein induced an 
increase in mean plasma lutein by a factor of 5 and a linear 4-week increase in 
relative macular pigment (MP) density of 4% to 5% (Berendschot et al., 2000). 
 
An age-related decline in the MPOD was found in a group from a Northern 
European population using heterochromic flicker photometry.  This study also 
found significantly less MP in eyes judged to be at high risk for AMD compared 
with age-matched controls (Beatty et al., 2001).  A previous study had also 
found a statistically significant inverse relationship between the MPOD and age 
among subjects living in Arizona (Hammond and Caruso-Avery, 2000).  These 
results contrast with the results of earlier studies on the effects of aging on 
MPOD (Werner et al., 1987; Bone et al., 1988), although these trials did not 
take into account more recently identified risk factors such as gender (EDCCS 
Group, 1992; Klein et al., 1992; Vinding, 1995), and smoking (Klein et al., 1993; 
Seddon et al., 1996; Smith and Mitchell, 1996; Vingerling et al., 1996; 
Tamakoshi et al., 1997; Hawkins et al., 1999).  A further case-control study 
found an inverse association between risk of AMD and MPOD, although the 
authors state that this does not imply a causal association (Bone et al., 2001). 
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Protective mechanisms of lutein and zeaxanthin 
Lutein and zeaxanthin are believed to protect the retina in two ways.  Firstly, 
they filter short wavelengths of light and so reduce the oxidative effect of blue 
light (Ham, 1983; Ham et al., 1984). These carotenoids act effectively as a blue-
light filter for a number of reasons. Action spectrum for light-induced damage 
shows a maximum at 400nm and 450nm which is consistent with the absorption 
spectrum of macular pigment (Ham et al., 1984)  This is known as the ‘blue light 
hazard function’ (Ham and Mueller, 1989).  As previously mentioned, the 
macular pigment reaches its highest concentration in the foveal region, and it 
has been shown that the orientation of the pigment molecules enhances light 
absorption (Farber et al., 1985; Beatty et al., 1999).  The distribution of macular 
pigment through photoreceptor cells means that each cell screens other cells as 
well as itself due to the lateral course of the axons (Farber et al., 1985). 
  
Secondly, carotenoids limit oxidant stress of tissue resulting from metabolism 
and light (Ham, 1983; Schalch, 1992; Khachik et al., 1997).  There are two 
known mechanisms by which carotenoids quench free radicals.  Energy transfer 
to the carotenoid quenches singlet oxygen.  The carotenoid is then able to relax 
without destructive bond-breaking. The ability to quench free radicals depends 
on the conjugate double bonds within their molecular structure. Carotenoids are 
also believed to react with peroxy radicals which are involved with lipid 
peroxidation (Landrum and Bone, 2001). 
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Conclusion 
It is difficult to compare the results of the studies described here as there are 
many variables.  The results of zinc supplementation determined by Newsome 
et al. (1988), were not confirmed by Stur et al. (1996). This is important in that 
the participants of this second trial were at higher risk of AMD because they 
already had an exudative form of the condition in one eye.  It is interesting to 
note that a positive effect of zinc supplementation was determined from the 
Newsome et al. (1988) trial, despite the lower calculated degree of precision. 
Widespread use of zinc supplementation was not recommended due to the risk 
of copper deficiency anaemia (Dunlap et al., 1974; Fischer et al., 1983; 
Flanagan et al., 1983) as well as a potential side effect of worsening of 
cardiovascular disease.  People with ischaemic heart disease have been shown 
to have reduced levels of cardiac and leucocyte copper, as well as decreased 
activity of some copper-dependant enzymes (Klevay, 2000).  
 
The AREDS formed a much larger zinc intervention trial, and found a 
‘suggestive’ reduction in the risk of progression to advanced AMD in category 3 
and 4 participants (see table 6).  These results may suggest a beneficial role of 
zinc in this subsection of AMD patients, particularly those who smoke and are 
therefore contraindicated from beta-carotene.   
The Newsome and Stur studies used 200mg zinc sulphate; the AREDS used 
80mg zinc oxide.  Although zinc oxide has the relatively poorer bioavailibility of 
the two, the most bioavailable forms of zinc are zinc citrate, gluconate, 
monomethionine, and picolinate (Lazarides, 1997).  Using a more bioavailable 
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form of zinc may have produced a greater treatment effect, but is likely to have 
also induced more toxicity issues. 
 
Although the amounts of vitamin E used in the VECAT and AREDS differ, 
(335mg and 273mg respectively), these amounts are both much higher than 
RDA (15mg).  The different conclusions made by these trials could suggest that 
supplementation with vitamin E is only effective in combination with other 
nutrients.  The negative result from the ATBC trial accommodates this theory, 
although a lower dose of 50mg was used and it was combined with 20mg of 
beta-carotene.  This trial differs from the others in that only male smokers were 
enrolled.  There was no evidence for a role of nutritional supplementation in 
slowing the progression of ARM in any of these three studies.  The data from 
the AREDS category 2 participants is positive for patients with extensive small 
drusen, pigment abnormalities, or at least one intermediate sized druse, as it 
indicates a 1.3% probability of progression to advanced AMD after 5 years.  The 
antioxidant arm of the AREDS trial contains the same nutrients as the Visaline® 
trial with the exception of buphenine. However, the doses are vastly different 
making comparison impossible.  
 
There is evidence to support the hypotheses that antioxidants such as vitamin 
C, E, carotenoids and zinc may play a role in reducing the risk of progression of 
AMD (The AREDS Research Group, 2001; Richer et al., 2002).  Lutein and 
zeaxanthin were considered for inclusion in the AREDS formulation, and it is 
known that they are oxygenated carotenoids, which make up the MP.  Their role 
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in the treatment of AMD has been investigated in the LAST, where results 
indicated reversal of AMD symptoms.  These findings may represent a 
breakthrough in the therapeutic approach to AMD management, and warrant 
further investigation. 
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Table 1: RCTs included in the review 
Name of study 
 
Reference 
 
Location 
 
Follow-up period 
 
Completion date 
Zinc in macular degeneration 
Newsone et al. 
1988 
USA 1-2 years - 
Visaline
®
 in the treatment of AMD 
Kaiser et  al. 
(1995) 
Switzerland 6 months - 
Zinc and the second eye in AMD Stur et al. (1996) Austria 2 years 1994 
Alpha-Tocopherol, Beta-Carotene Trial 
(ATBC) 
Teikari et al. 
(1998) 
Finland 5-8 years 1993 
Age-Related Eye Disease Study (AREDS) 
The AREDS 
Research Group, 
(2001) 
USA 6.3 years (average) 2001 
Vitamin E, Cataract and AMD Trial 
(VECAT) 
Taylor et al. 
(2002) 
Australia 4 years 2000 
The Lutein Antioxidant Supplementation 
Trial (LAST) 
Richer et al. 
(2002) 
USA 1 year - 
Table 2: Nutrients included in RCT formulations 
TRIAL NUTRIENTS INCLUDED 
AMOUNT 
(mg) 
 Zinc in macular degeneration Zinc 200 
Visaline
®
 
  
  
Vitamin C 
Vitamin E 
Beta-carotene 
Buphenine 
200 
40 
40 
1.5* 
Zinc and the second eye in ARMD  Zinc 200 
 
ATBC  
Vitamin E 
Beta-carotene 
50 
20 
AREDS 
Vitamin C 
Vitamin E 
Beta-carotene 
Zinc 
Copper 
500 
273 
15 
80 
2 
VECAT Vitamin E 335 
Lutein Antioxidant 
Supplementation  Trial 
Lutein 
Lutein/antioxidants (not specified) 
10 
10 
* Buphenine is not a nutrient but a beta-adrenergic stimulant, which increases 
peripheral blood flow, mainly by acting directly on arteries and arterioles of 
skeletal muscle. 
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Table 3: Recommended Daily Allowances (RDA) (mg) 
 Male Female Male Smoker Female Smoker 
Vitamin C 90 75 125 110 
Vitamin E 15 15 15 15 
Zinc 15 15 15 15 
Lutein 6 6 6 6 
Table 4: Trials for which R values could be 
calculated  
Trial R value 
Visaline
®
 88.5 
 Zinc in the second eye 
 (Stur et al. 1996) 
16.1 
 
Zinc in macular degeneration 
(Newsome et al. 1988) 
71.9 
Table 5: Definitions of AREDS ARM/AMD categories 
Category Definition 
1 
No drusen or drusen <63μm with an area <125μm 
diameter circle and no pigment abnormalities 
2 
Small drusen (<63μm) with an area ≤125μm 
diameter circle with possible pigment 
abnormalities but no geographical atrophy 
OR no drusen if pigment abnormalities are 
present 
3a 
Intermediate drusen (≥63<125μm) with ≥360μm 
diameter circle if soft indistinct drusen are 
present, ≥656μm diameter circle if soft indistinct 
drusen are absent. Pigment abnormalities could 
be absent or present but geographical atrophy 
was absent  
  OR large ≥125μm drusen 
  
OR no drusen required if non-central geographic 
atrophy is present 
3b 
First eye same as category 3a.  VA < 20/32 in the 
second eye not due to AMD 
4a 
First eye same as category 1, 2 or 3a with 
advanced AMD in the second eye 
4b 
First eye same as category 1, 2, or 3a with VA < 
20/32 in the second eye due to AMD but not 
presenting advanced AMD.  
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Table 6: Probability of AMD event for each category 
AMD category Probability of AMD event at year 5 
2 
3 
4 
1.3% 
18.3% 
42.9% 
Table 7: Probability of AMD event by treatment arm 
Treatment arm Probability of AMD event at year 5 
Placebo 
Antioxidants 
Zinc 
Zinc + antioxidants 
27.8% 
22.6% 
21.6% 
20.2% 
Table 8: Probability of VA event by treatment arm 
Treatment arm Probability of VA event at year 5 
Placebo 
Antioxidants 
Zinc 
Zinc + antioxidants 
29.1% 
25.9% 
25.5% 
23.1% 
Table 9: Increase in median serum levels from baseline to 
year 1 in the antioxidants arm 
Antioxidant % increase 
Vitamin C 25 
Vitamin E-cholesterol 
Ratio 
82 
Beta-carotene 485 
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Table 10: Changes in median serum levels in the placebo 
and zinc arms from baseline to year 5 
 
Antioxidant 
       % change 
Placebo          Zinc 
Vitamin C -7 -12 
Vitamin E-cholesterol 
Ratio 
+6 +6 
Beta-carotene +4 0 
Table 11: VECAT early AMD grading system 
Feature Grading of photographs 
Clinical 
grading 
Early AMD 
1 
Soft intermediate or soft distinct or 
soft indistinct or pigment changes 
(hyperpigmentation or 
hypopigmentation) 
Not 
applicable 
Early AMD 
2 
Soft intermediate or soft distinct or 
soft indistinct and pigment 
changes (hyperpigmentation or 
hypopigmentation) 
Not 
applicable 
Early AMD 
3 
Soft distinct or soft indistinct or 
pigment changes 
(hyperpigmentation or 
hypopigmentation) 
Large/soft 
drusen or 
non-
geographical 
RPE atrophy 
Early AMD 
4 
Soft distinct or soft indistinct and 
pigment changes 
(hyperpigmentation or 
hypopigmentation) 
Large/soft 
drusen and 
non-
geographical 
RPE atrophy 
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Abbreviated title 
AMD and nutrition – a review of randomised controlled trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12: Summary of RCT results 
 RCT Nutrients Included Effect Seen 
AREDS Vit C, Vit E, beta-carotene, zinc 
Positive result in 
combination 
ATBC Vit E, beta-carotene No effect 
VECAT Vit E No effect 
Visaline
®
 in the treatment of AMD Vit C, Vit E, beta-carotene, buphenine No effect 
Zinc in macular degeneration Zinc Positive effect 
Zinc and the second eye in AMD Zinc No effect 
LAST Lutein, antioxidants Positive effect 
Table 9: Summary of RCT results  
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Figure 4 
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Captions to figures 
 
Figure 1: Visual acuity loss with time in the Newsome  
et al. (1988) study 
 
Figure 2: Change in drusen grading by observer in  
the Newsome et al. (1988) study 
 
Figure 3: Change in mean distance visual acuity between treatment  
groups in the Visaline® study (Kaiser et al. 1995) 
 
Figure 4: Distribution of ARM/AMD by treatment group in the ATBC  
Study (Teikari et al. 1998) 
 
Figure 5: Probability of AMD event at year 5 by treatment arm (Archives of  
Ophthalmology (2001) 119, 1417-1436)  
 
 
 
 
